Gilead Sciences, Inc.  

(Public, NASDAQ:GILD)   Watch this stock  
Find more results for GILD
104.83
+0.65 (0.62%)
Jan 30 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 103.73 - 106.27
52 week 63.50 - 116.83
Open 104.33
Vol / Avg. 13.61M/19.18M
Mkt cap 158.15B
P/E 18.54
Div/yield     -
EPS 5.65
Shares 1.51B
Beta 0.73
Inst. own 88%
Feb 10, 2015
Gilead Sciences Inc at Biotechnology Industry Organization CEO & Investor Conference - 10:00AM EST - Add to calendar
Feb 3, 2015
Q4 2014 Gilead Sciences Inc Earnings Call - 4:30PM EST - Add to calendar
Feb 3, 2015
Q4 2014 Gilead Sciences Inc Earnings Release - 4:05PM EST - Add to calendar
Jan 13, 2015
Gilead Sciences Inc at JPMorgan Healthcare Conference
Dec 3, 2014
Gilead Sciences Inc at Piper Jaffray Healthcare Conference
Dec 2, 2014
Gilead Sciences Inc at NASDAQ OMX Investor Program
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 45.09% 27.29%
Operating margin 57.59% 40.39%
EBITD margin - 43.46%
Return on average assets 36.39% 13.98%
Return on average equity 73.88% 29.75%
Employees 6,100 -
CDP Score - -

Address

333 LAKESIDE DR
FOSTER CITY, CA 94404
United States - Map
+1-650-5743000 (Phone)
+1-650-5789264 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha

Description

Gilead Sciences, Inc. (Gilead) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Gilead�s primary areas of focus include human immunodeficiency virus (HIV)/AIDS, liver diseases, such as hepatitis B and C and cardiovascular/metabolic and respiratory conditions. The Company has operations in North America, Europe and Asia Pacific. The Company�s products include Atripla, Truvada, Viread, Complera/Eviplera, Emtriva, Hepsera, Letairis, Ranexa, Lexiscan/Rapiscan, AmBisome, Vistide, Macugen, Cayston and Tamiflu. In January 2012, the Company acquired Pharmasset, Inc. On February 8, 2013, its subsidiary, acquired YM BioSciences Inc.

Officers and directors

John C. Martin Ph.D. Chairman of the Board, Chief Executive Officer
Age: 62
Bio & Compensation  - Reuters
John F. Milligan Ph.D. President, Chief Operating Officer
Age: 53
Bio & Compensation  - Reuters
Robin L. Washington Chief Financial Officer, Executive Vice President
Age: 51
Bio & Compensation  - Reuters
Norbert W. Bischofberger Ph.D. Executive Vice President - Research and Development, Chief Scientific Officer
Age: 58
Bio & Compensation  - Reuters
Gregg H. Alton Executive Vice President - Corporate and Medical Affairs
Age: 48
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Paul R. Carter Executive Vice President - Commercial Operations
Age: 53
Bio & Compensation  - Reuters
Andrew Cheng M.D., Ph.D. Executive Vice President - HIV Therapeutics and Development Operations
Bio & Compensation  - Reuters
John G. McHutchison M.D. Executive Vice President
Bio & Compensation  - Reuters
Taiyin Yang Ph.D. Executive Vice President - Pharmaceutical Development and Manufacturing
Age: 60
Bio & Compensation  - Reuters
John F. Cogan Jr., P Lead Independent Director
Bio & Compensation  - Reuters